The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

India has launched a new digital platform, Ayush Nivesh Saarthi, in a move aimed at mainstreaming India’s traditional ...

Elon Musk's clash with Donald Trump threatens SpaceX’s $22B in U.S. contracts, raising concerns for NASA, national security, ...